Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$3.05 USD
0.00 (0.00%)
Updated May 24, 2024 04:00 PM ET
After-Market: $3.03 -0.02 (-0.66%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Galectin Therapeutics Inc. [GALT]
Reports for Purchase
Showing records 61 - 80 ( 107 total )
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Another Shot on Goal: GR-MD-02 Works in Metastatic Melanoma; Increased PT $10
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NASH-CX Data in December Brings Early Christmas Gifts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Titbit on NASH-CX at the Liver Meeting
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Healthcare - WEEKLY NASH NEWSLETTER: KICK OFF AASLD WITH OUR CALENDAR
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and a 12-month price target of $8/share.
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Safety of GR-MD-02 in NASH-CX Trial Confirmed by DSMB; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
We are dropping coverage of GALT shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
1Q17 Recap: Top-line Data Readout of NASH-CX Still On Track for December; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NASH SPLASH: Highlights From Our Inaugural NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Results of NASH-CX in December Are a Major Stock Catalyst; Upgrading to Buy; PT to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Agenda for Our First Annual NASH Investor Conference on April 3 in NY
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NASH-CX Data On Track for December 2017; Affirm Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
3Q Recap: NASH Cirrhosis Data on Track; Settling in for a Long Wait; Dropping PT to $0.60
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NASH-FX Failure Likely Degrades the Prognosis for NASH-CX; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E